Miller, Cheryl N
Mayo Clinic
Frederick National Laboratory for Cancer Research
Citations 1
Concordance of SARS-CoV-2 Antibody Results during a Period of Low Prevalence
Schlueter, David J., Garbett, Shawn , Ratsimbazafy, Francis, Karlson, Elizabeth W. , Cicek, Mine , Malin, Bradley , Ohno‐Machado, Lucila , Williams, Carolyn , Goldstein, David B. , Kouame, Aymone, Ramirez, Andrea H. , Schully, Sheri D. , Miller, Cheryl N , Pinto, Ligia A , Althoff, Keri N. , Anton‐Culver, Hoda , Chen, Qingxia , Thomsen, Isaac P. , Gebo, Kelly A
mSphere | September 29, 2022 | Volume: 7 | Issue: 5 | Pages: No page available
What is the agreement of commercial SARS-CoV-2 immunoglobulin G (IgG) assays during a time of low coronavirus disease 2019 (COVID-19) prevalence and no vaccine availability? Serological tests produced concordant results in a time of low SARS-CoV-2 prevalence and no vaccine availability, driven largely by the proportion of samples that were negative by two immunoassays. The CDC recommends two sequential tests for positivity for future pandemic preparedness.